BRPI0606360A2 - método para melhorar a apoptose, método para tratar uma desordem proliferativa e método para tratar células cancerosas - Google Patents

método para melhorar a apoptose, método para tratar uma desordem proliferativa e método para tratar células cancerosas

Info

Publication number
BRPI0606360A2
BRPI0606360A2 BRPI0606360-8A BRPI0606360A BRPI0606360A2 BR PI0606360 A2 BRPI0606360 A2 BR PI0606360A2 BR PI0606360 A BRPI0606360 A BR PI0606360A BR PI0606360 A2 BRPI0606360 A2 BR PI0606360A2
Authority
BR
Brazil
Prior art keywords
treating
cancer cells
proliferative disorder
apoptosis
death receptor
Prior art date
Application number
BRPI0606360-8A
Other languages
English (en)
Inventor
Avi J Ashkenazi
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0606360A2 publication Critical patent/BRPI0606360A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

MéTODO PARA MELHORAR A APOPTOSE, MéTODO PARA TRATAR UMA DESORDEM PROLIFERATIVA E MéTODO PARA TRATAR CéLULAS CANCEROSAS. São fornecidos métodos de uso dos ligantes de receptor de morte, tais como polipeptídeos de Apo-2 ligante/TRAIL ou anticorpos para receptor de morte, e inibidores de EGFR para tratar condições patológicas como, por exemplo, o câncer. As incorporações da invenção incluem métodos de uso da Apo2LITRAIL ou anticorpos para receptor de morte, tais como anticorpos DR5 e DR4, combinados com inibidores de EGFR, como Tarceva
BRPI0606360-8A 2005-02-18 2006-02-16 método para melhorar a apoptose, método para tratar uma desordem proliferativa e método para tratar células cancerosas BRPI0606360A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/061,258 US20060188498A1 (en) 2005-02-18 2005-02-18 Methods of using death receptor agonists and EGFR inhibitors
PCT/US2006/005459 WO2006089015A2 (en) 2005-02-18 2006-02-16 Methods of using death receptor agonists and egfr inhibitors

Publications (1)

Publication Number Publication Date
BRPI0606360A2 true BRPI0606360A2 (pt) 2009-06-23

Family

ID=36912953

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606360-8A BRPI0606360A2 (pt) 2005-02-18 2006-02-16 método para melhorar a apoptose, método para tratar uma desordem proliferativa e método para tratar células cancerosas

Country Status (13)

Country Link
US (1) US20060188498A1 (pt)
EP (1) EP1853300B1 (pt)
JP (2) JP2008532937A (pt)
KR (1) KR20070110852A (pt)
CN (1) CN101180072A (pt)
AU (1) AU2006214292A1 (pt)
BR (1) BRPI0606360A2 (pt)
CA (1) CA2595931A1 (pt)
IL (1) IL184827A0 (pt)
NO (1) NO20074740L (pt)
RU (1) RU2429006C2 (pt)
WO (1) WO2006089015A2 (pt)
ZA (1) ZA200706859B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060132006A (ko) * 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
US8685939B2 (en) * 2008-11-06 2014-04-01 Wayne State University Vaccine targeting cellular death receptor DR5
JP2013505944A (ja) * 2009-09-24 2013-02-21 シアトル ジェネティックス， インコーポレイテッド Ｄｒ５リガンド薬物結合体
MX2012013144A (es) * 2010-05-14 2012-11-30 Amgen Inc Agonistas mejorados de receptor de muerte.
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
ITPD20110091A1 (it) * 2011-03-24 2012-09-25 Univ Padova Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico.
EP2704735A1 (en) * 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
CN102675225A (zh) * 2012-05-16 2012-09-19 浙江理工大学 一种盐酸埃罗替尼的合成方法
RU2580220C2 (ru) * 2012-11-07 2016-04-10 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) РЕКОМБИНАНТНАЯ ПЛАЗМИДА рСрG-СytDA/upp ДЛЯ ЭКСПРЕССИ ГИБРИДНОГО БЕЛКА ЦИТОЗИНДЕЗАМИНАЗА-УРАЦИЛФОСФОРИБОЗИЛ ТРАНСФЕРАЗА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА рСрG-СytDA/upp/VP22 ДЛЯ ЭКСПРЕССИИ ГИБРИДНОГО БЕЛКА ЦИТОЗИНДЕЗАМИНАЗА-УРАЦИЛФОСФОРИБОЗИЛ ТРАНСФЕРЕЗА-VP22, ЛЕЧЕБНАЯ КОМПОЗИЦИЯ ДЛЯ ТЕРАПИИ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ И СПОСОБ ЕЕ ПРИМЕНЕНИЯ
MX364558B (es) * 2013-10-04 2019-04-29 Univ Basel INHIBIDORES DE PI3K Y mTOR CONFORMACIONALMENTE RESTRINGIDOS.
CN103833853B (zh) * 2013-12-25 2019-05-17 河南大学 新型死亡受体激动性多价抗体及其在制备抗肿瘤药物中的应用
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
EP3125935B1 (en) * 2014-04-03 2019-10-23 Merck Patent GmbH Combinations of cancer therapeutics
NO2776305T3 (pt) * 2014-04-23 2018-01-27
MX2017007372A (es) 2014-12-12 2017-11-06 Merck Patent Gmbh Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cancer con un inhibidor de factor de crecimiento epidermico (egfr).
CN105801495A (zh) * 2014-12-31 2016-07-27 徐州万邦金桥制药有限公司 一种盐酸厄洛替尼合成纯化方法
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EA201892260A1 (ru) * 2016-04-07 2019-03-29 Дзе Джонс Хопкинс Юниверсити Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
CA3027705A1 (en) * 2016-06-17 2017-12-21 The Trustees Of The University Of Pennsylvania Compounds, compositions and methods for prevention and/or treatment of cancer
CN110156897B (zh) * 2018-02-08 2022-09-20 四川大学华西医院 一种包含TRAIL和IgG结合结构域的融合蛋白及其用途
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CN119371319A (zh) * 2024-10-25 2025-01-28 安徽尖峰北卡药业有限公司 一种用于埃罗替尼中间体生产工艺及其生产系统

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
DK0851925T3 (da) 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EA001595B1 (ru) * 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
AR007857A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
US7452538B2 (en) * 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
EA003786B1 (ru) * 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
EP1501866A4 (en) * 2001-10-02 2006-02-08 Genentech Inc VARIANTS OF THE LIGAND APO-2 AND USES THEREOF
EP1450847B1 (en) * 2001-11-13 2010-09-29 Genentech, Inc. APO2 ligand/ TRAIL formulations and uses thereof
RU2240125C2 (ru) * 2002-11-12 2004-11-20 Государственное учреждение Гематологический научный центр РАМН СПОСОБ ЭФФЕКТИВНОЙ ИНДУКЦИИ АПОПТОЗА В СУСПЕНЗИОННЫХ КУЛЬТУРАХ ОПУХОЛЕВЫХ PH$$$ КЛЕТОК КОСТНОГО МОЗГА И ПЕРИФЕРИЧЕСКОЙ КРОВИ БОЛЬНЫХ Ph+ ЛЕЙКОЗАМИ С ПОМОЩЬЮ АНТИСЕНС ОЛИГОНУКЛЕОТИДОВ, СПЕЦИФИЧНЫХ К МРНК ГЕНОВ, ИНГИБИРУЮЩИХ АПОПТОЗ
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
EP1754713B1 (en) * 2003-05-09 2009-02-25 Genentech, Inc. Apo2L (Trail) receptor binding peptides and uses thereof

Also Published As

Publication number Publication date
RU2429006C2 (ru) 2011-09-20
ZA200706859B (en) 2008-11-26
JP2008532937A (ja) 2008-08-21
EP1853300A2 (en) 2007-11-14
AU2006214292A1 (en) 2006-08-24
JP2012229237A (ja) 2012-11-22
US20060188498A1 (en) 2006-08-24
CN101180072A (zh) 2008-05-14
IL184827A0 (en) 2008-08-07
EP1853300B1 (en) 2014-07-23
RU2007134568A (ru) 2009-03-27
WO2006089015A3 (en) 2007-08-23
KR20070110852A (ko) 2007-11-20
CA2595931A1 (en) 2006-08-24
WO2006089015A2 (en) 2006-08-24
NO20074740L (no) 2007-11-14

Similar Documents

Publication Publication Date Title
BRPI0606360A2 (pt) método para melhorar a apoptose, método para tratar uma desordem proliferativa e método para tratar células cancerosas
EA201190210A1 (ru) Ингибиторы связывания киназы с белком
MX2007006640A (es) Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
WO2007149427A3 (en) Tyrosine kinase inhibitors
UA116187C2 (uk) ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
BR112012011529A2 (pt) sistema de laser, e, método para escanear um feixe de laser
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
BR112012011528A2 (pt) métodos para inibir uma proteína quinase e para tratar uma doença associada com atividade de quinase, e, composto
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
WO2010056309A3 (en) Methods and compositions related to targeting monoacylglycerol lipase
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
MY148468A (en) Compounds and methods for kinase modulation, and indications therefor
MX2009006688A (es) Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
EA201190025A1 (ru) ПРИМЕНЕНИЕ АНТАГОНИСТОВ DR6 И p75 ДЛЯ ПРОМОТИРОВАНИЯ ВЫЖИВАНИЯ КЛЕТОК НЕРВНОЙ СИСТЕМЫ
EA200970738A1 (ru) Ингибиторы активности akt
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
BRPI0821151A2 (pt) Derivados de pirazol e uso dos mesmos como inibidores de quinases dependentes de ciclina
GB0724532D0 (en) Trail variants for treating cancer
EA200801732A1 (ru) Модуляторы ауроракиназы, способы их получения и их применение
EA200901249A1 (ru) Ингибиторы связывания протеинкиназ
BRPI0515604A (pt) método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada
EA201001266A1 (ru) Эффективные противоопухолевые парамиксовирусы

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL